Literature DB >> 6182968

Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients.

R D Hull, J Hirsh, D L Sackett, G L Stoddart.   

Abstract

Because death due to pulmonary embolism is relatively rare following general surgery, many question the need for prophylaxis. In addition, there has been reluctance to apply new interventions whose cost-effectiveness has not been adequately evaluated. A cost-effectiveness analysis based on over 1000 high-risk patients undergoing abdominothoracic surgery, with effectiveness measured in terms of numbers of deaths from pulmonary embolism averted, has shown subcutaneous administration of heparin in low doses starting 2 hours before the operation to be the most cost-effective of several active approaches to prophylaxis. It averted seven of the eight deaths expected without active prophylaxis per 1000 such patients and cost half as much as the traditional approach of intervening only when venous thromboembolism becomes clinically apparent. Intravenous administration of dextran, although effective, was expensive, and leg scanning with iodine-125-labelled fibrinogen was extremely expensive. Intermittent pneumatic compression of the legs was inexpensive, but, as with leg scanning, its effectiveness has not been determined in randomized trials.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6182968      PMCID: PMC1862293     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  16 in total

Review 1.  Diagnosis of venous thromboembolism.

Authors:  A S Gallus; J Hirsh; R Hull; W G Aken
Journal:  Semin Thromb Hemost       Date:  1976-04       Impact factor: 4.180

2.  Prevention of venous thrombosis with small, subcutaneous doses of heparin.

Authors:  A S Gallus; J Hirsh; S E O'Brien; J A McBride; R J Tuttle; M Gent
Journal:  JAMA       Date:  1976-05-03       Impact factor: 56.272

Review 3.  Fibrinogen uptake test for detection of deep vein thrombosis--a review of current practice.

Authors:  V V Kakkar
Journal:  Semin Nucl Med       Date:  1977-07       Impact factor: 4.446

4.  125-I-labelled fibrinogen test adapted for routine screening for deep-vein thrombosis.

Authors:  V V Kakkar; A N Nicolaides; J T Renney; J R Friend; M B Clarke
Journal:  Lancet       Date:  1970-03-14       Impact factor: 79.321

5.  The detection of venous thrombosis of the legs using 125-I-labelled fibrinogen.

Authors:  C Flanc; V V Kakkar; M B Clarke
Journal:  Br J Surg       Date:  1968-10       Impact factor: 6.939

Review 6.  Treatment of venous thromboembolic disease.

Authors:  A S Gallus; J Hirsh
Journal:  Semin Thromb Hemost       Date:  1976-04       Impact factor: 4.180

7.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

8.  Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin.

Authors:  J Kiil; J Kiil; F Axelsen; D Andersen
Journal:  Lancet       Date:  1978-05-27       Impact factor: 79.321

9.  Prevention of early postoperative deep vein thrombosis by intermittent compression of the leg during surgery.

Authors:  S Sabri; V C Roberts; L T Cotton
Journal:  Br Med J       Date:  1971-11-13

10.  Prevention of postoperative deep vein thrombosis in patients with malignant disease.

Authors:  V C Roberts; L T Cotton
Journal:  Br Med J       Date:  1974-03-02
View more
  15 in total

Review 1.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

Review 2.  Venous thromboembolism: epidemiology, diagnosis, prevention.

Authors:  D M Becker
Journal:  J Gen Intern Med       Date:  1986 Nov-Dec       Impact factor: 5.128

3.  Prophylaxis for venous thromboembolism in hip fracture surgery: total costs and cost effectiveness in The Netherlands.

Authors:  W E Mol; T C Egberts
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

Review 4.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 5.  Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism.

Authors:  D R Anderson; B J O'Brien
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

6.  Efficacy and safety profiles of mechanical and pharmacological thromboprophylaxis.

Authors:  Mario Ganau; Gianfranco K I Ligarotti; Marco Meloni; Salvatore Chibbaro
Journal:  Ann Transl Med       Date:  2019-09

Review 7.  Can thrombus age guide thrombolytic therapy?

Authors:  Christopher Czaplicki; Hassan Albadawi; Sasan Partovi; Ripal T Gandhi; Keith Quencer; Amy R Deipolyi; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 8.  The pathogenesis and prevention of thromboembolic complications in patients undergoing total hip replacement.

Authors:  D K Potyk; H J Tabbarah
Journal:  J Gen Intern Med       Date:  1993-04       Impact factor: 5.128

9.  Mammographic screening: measurement of the cost in a population based programme in Victoria, Australia.

Authors:  S F Hurley; P M Livingston; N Thane; L Quang
Journal:  J Epidemiol Community Health       Date:  1994-08       Impact factor: 3.710

Review 10.  Venous thromboembolism in Pakistan: a neglected research agenda.

Authors:  Abdul Ahad Khan; Syed Nabeel Zafar
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.